5% Off
Ceftron500 mg/via
Square Pharmaceuticals PLC.
৳190.00
Add to cart
G-Ceftriax500 mg/vial
IV Injection
By
Best PriceTk /
1
Alternatives
Price
Medicine overview
Indications of G-Ceftriax 500 mg/vial
G-Ceftriax 500 mg/vial is indicated for the treatment of the following major infections:
Lower respiratory tract infections
Acute Bacterial Otitis Media
Skin and skin structure infections
Urinary tract infections
Gonorrhea
Bacterial Septicemia
Bone and joint infections
Meningitis
Prevention of postoperative infections
Perioperative prophylaxis of infections associated with surgery
Theropeutic Class
Third generation Cephalosporins
Pharmacology
G-Ceftriax 500 mg/vial is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic.
Absorption
It has potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms.
Distribution
Like other cephalosporins and penicillins, G-Ceftriax 500 mg/vial kills bacteria by interfering with the synthesis of the bacterial cell wall.
Metabolism
A remarkable feature of G-Ceftriax 500 mg/vial is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. G-Ceftriax 500 mg/vial is not metabolized in the body.
Excretion
A remarkable feature of G-Ceftriax 500 mg/vial is its relatively long plasma elimination half-life of about 6 to 9 hours, which makes single or once-daily dosage of the drug appropriate for most patients. About 40-65% of a dose of G-Ceftriax 500 mg/vial is excreted unchanged in the urine; the remainder is excreted in the bile and ultimately found in the feces as unchanged drug and microbiologically inactive compound.
Dosage of G-Ceftriax 500 mg/vial
Adult
Dosage:The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day)
Notes:Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 4 gm/day Uncomplicated gonococcal infections: 250 mg IM as a single dose Surgical prophylaxis: 1 g IV as a single dose 30 to 120 minutes before surgery Infants and Children (01 month or older): The usual dose is 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections: 50 to 75 mg/kg IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 2 gm/day Acute bacterial otitis media: 50 mg/kg IM in single dose; Maximum dose: 1 gm/day Meningitis: 100 mg/kg IV or IM in single daily dose or (or in equally divided doses twice a day); Maximum dose: 4 gm/day Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual duration is 4 to 14 days; in complicated infections, longer therapy may be required
| Condition | Dosage | Notes |
|---|---|---|
| Adult | The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day) | Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 4 gm/day Uncomplicated gonococcal infections: 250 mg IM as a single dose Surgical prophylaxis: 1 g IV as a single dose 30 to 120 minutes before surgery Infants and Children (01 month or older): The usual dose is 50 to 75 mg/kg intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections: 50 to 75 mg/kg IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 2 gm/day Acute bacterial otitis media: 50 mg/kg IM in single dose; Maximum dose: 1 gm/day Meningitis: 100 mg/kg IV or IM in single daily dose or (or in equally divided doses twice a day); Maximum dose: 4 gm/day Duration of therapy: Continue for more than 2 days after signs and symptoms of infection have disappeared. Usual duration is 4 to 14 days; in complicated infections, longer therapy may be required |
Administration of G-Ceftriax 500 mg/vial
Preparation of Solutions for Intramuscular / Intravenous Injections:
For Intramuscular Injection: 250 mg or 500 mg G-Ceftriax 500 mg/vial should be dissolved in 2 ml Lidocaine HCI 1% injection or 1 g G-Ceftriax 500 mg/vial in 3.5 ml of Lidocaine HCI 1% injection.
For Intravenous Injection: 250 mg or 500 mg G-Ceftriax 500 mg/vial should be dissolved in 5 ml of Water for injection or 1 g G-Ceftriax 500 mg/vial in 10 ml of Water for injection USP or 2 g G-Ceftriax 500 mg/vial in 20 ml of Water for injection.
The injection should be administered over 2-4 minutes, by Intramuscular or Intravenous injection or by tubing infusion over a period of 30 minutes at concentration between 10 mg/mL and 40 mg/mL. Before starting treatment through G-Ceftriax 500 mg/vial injection, patient tolerance test should be checked by administration of a test dose. (The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 6 hours at room temperature or 24 hours at 5°C).
Interaction of G-Ceftriax 500 mg/vial
No drug interactions have been reported.
Contraindications
G-Ceftriax 500 mg/vial should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.
Side Effects of G-Ceftriax 500 mg/vial
Common (>1%)
- nausea and vomiting
- stomatitis and glossitis
- cutaneous reactions including rash
- pruritus
- urticaria
- edema and erythema multiforme
Uncommon
- hematologic reactions including eosinophilia
- thrombocytopenia
- leucopenia
- anemia and neutropenia
- hepatic reactions including elevations of SGOT or SGPT
- bilirubinemia
Rare / Long-term
- CNS reactions including nervousness
- confusion
- sleep disturbances
- headache
- hyperactivity
- convulsion
Pregnancy & Lactation
Its safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of G-Ceftriax 500 mg/vial are excreted in human milk. Caution should be exercised when G-Ceftriax 500 mg/vial is administered to a lactating mother.
Precautions & Warnings
As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Anaphylactic shock requires immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid. In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. This condition was reversible on discontinuation or completion of G-Ceftriax 500 mg/vial therapy. Even if such findings are associated with pain, conservative, nonsurgical management is recommended. During prolonged treatment the blood picture should be checked at regular intervals.
Overdose Effects of G-Ceftriax 500 mg/vial
There is no specific antidote. Treatment of overdosage should be symptomatic.
Storage Conditions
Vial store in a cool, dry place (below 30° C), away from light & moisture. Keep out of the reach of children.
Use In Special Populations
G-Ceftriax 500 mg/vial must not be given to neonates if the neonates is premature and newborn (up to 28 days of age).
Frequently Asked Questions
What is G-Ceftriax 500 mg/vial used for?
Ceftriaxone is indicated for the treatment of the following major infections: Lower respiratory tract infections Acute Bacterial Otitis Media Skin and skin structure infections Urinary tract infections Gonorrhea Bacterial Septicemia Bone and joint infections Meningitis Prevention of postoperative infections Perioperative prophylaxis of infections associated with surgery
What is the dosage of G-Ceftriax 500 mg/vial?
Adult: The usual dose is 1 to 2 gm by intravenous or intramuscular administration once a day (or in equally divided doses twice a day). Pneumonia, Bronchitis, Acute bacterial otitis media, Skin and skin structure infection, Urinary tract infections, Bacterial Septicemia, Bone and joint infections, Meningitis: 1 to 2 g IV or IM once a day (or in equally divided doses twice a day); Maximum dose: 4 g…
What are the side effects of G-Ceftriax 500 mg/vial?
Ceftriaxone is generally well tolerated. A few side effects such as gastro-intestinal effects including diarrhea, nausea and vomiting, stomatitis and glossitis; cutaneous reactions including rash, pruritus, urticaria, edema and erythema multiforme; hematologic reactions including eosinophilia, thrombocytopenia, leucopenia, anemia and neutropenia; hepatic reactions including elevations of SGOT or S…
Who should not take G-Ceftriax 500 mg/vial?
Ceftriaxone should not be given to patients with a history of hypersensitivity to cephalosporin antibiotics.
What precautions should be taken with G-Ceftriax 500 mg/vial?
As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient history is taken. Anaphylactic shock requires immediate countermeasures such as intravenous epinephrine followed by a glucocorticoid. In rare cases, shadows suggesting sludge have been detected by sonograms of the gallbladder. This condition was reversible on discontinuation or completion of Ceftriaxone…
Is G-Ceftriax 500 mg/vial safe during pregnancy and breastfeeding?
Its safety in human pregnancy has not been established. Therefore, it should not be used in pregnancy unless absolutely indicated. Low concentrations of Ceftriaxone are excreted in human milk. Caution should be exercised when Ceftriaxone is administered to a lactating mother.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.